Eli Lilly's recently approved breast cancer drug Verzenio (abemaciclib) has failed to meet a late-stage trial goal of improving non-small cell lung cancer patients' overall survival.
The company said that the trial was testing the drug in patients with advanced non-small cell lung cancer with mutation of the KRAS gene whose initial cancer therapies were ineffective.
Last month, the FDA approved the Verzenio to treat advanced breast cancer.
Lilly has several ongoing trials evaluating the drug in non-small cell lung cancer, including a combination trial with Keytruda or chemotherapy, and does not plan to discontinue them.
Read the Reuters report